{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-002644","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.651692+00:00","generated_at":"2026-05-28T04:47:56.002174+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CEO William Febbo departs OptimizeRx; receives $675K salary continuation + $450K bonus","bullets":["William J. Febbo stepped down as CEO and Board member effective Dec 31, 2024; separation agreement signed Jan 3, 2025.","Severance includes $450k/yr base salary for 18 months ($675k total) and a lump-sum $450k bonus.","COBRA premium reimbursement for 12 months; advisory services through March 31, 2025 with continued equity vesting.","12-month non-compete and non-solicit obligations apply; no replacement CEO named yet.","Equity awards continue to vest during the 3-month advisory period."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-002644","json":"https://secwatch.observer/filing/0001213900-25-002644.json","markdown":"https://secwatch.observer/filing/0001213900-25-002644.md","text":"https://secwatch.observer/filing/0001213900-25-002644.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/0001213900-25-002644-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/ea0227345-8k_optimize.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T04:47:56.002174+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7b920d2e7a","claim":"William J. Febbo departed as Chief Executive Officer at OptimizeRx Corp.","evidence_excerpt":"William J. Febbo stepped down from his positions as Chief Executive Officer (“CEO”) and Member of the Board of Directors (the “Board”) of OptimizeRx Corporation (the “Company”) effective as of December 31, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390025002644/0001213900-25-002644-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}